OBSAH
EDITORIAL................................................................................................................................................. 1
OBSAH ....................................................................................................................................................... 2
PROGRAM .............................................................................................................................................. 4
ODBORNÁ SYMPOZIA ...................................................................................................................... 9
Sympozium Společnosti pro biologickou psychiatrii: Klozapin v současné klinické praxi ........................... 9
Má koncept neurodiverzity své místo v psychiatrii? .................................................................................. 10
Olanzapin: klinický manuál pro praxi ......................................................................................................... 11
Ketaminem asistovaná psychoterapie (KAP) v ambulantní psychiatrické praxi ........................................ 12
Sympozium Psychiatrické společnosti ČLS JEP: Psychiatrie a společnost pod tlakem ........................... 13
Neinvazivní mozková stimulace (NIBS) v české psychiatrii: Klinická praxe a nové přístupy .................... 14
Možnosti léčby neuropsychiatrických příznaků demence ......................................................................... 16
Od vzniku poruch příjmu potravy k chronicitě, od farmakoterapie k psychoterapii ................................... 17
Sympozium Národního ústavu duševního zdraví ..................................................................................... 19
Výzkum kmenových buněk a organoidů mozku u neuropsychiatrických poruch ...................................... 21
Psychedelika, problémové děti psychofarmakologie VI – translační a preklinické studie ......................... 23
Farmakodetektivky 3 ................................................................................................................................. 24
Neurobiologie spánku u ADHD ................................................................................................................. 25
Psychedelika, problémové děti psychofarmakologie VI: Od klinických studií
ke klinickým vodítkům ............................................................................................................................... 25
NOVÝ VÝZKUM .................................................................................................................................. 27
CYPRI: nástroj pro identifikaci pacientů vhodných k farmakogenetickému vyšetření
v psychiatrii ............................................................................................................................................... 27
Roční výsledky po 7týdenním ústavním programu léčby závislosti u pacientů
se závislostí na alkoholu ........................................................................................................................... 27
Vizuální kognitivní evokované potenciály u akutně hospitalizovaných se schizofrenií ............................. 27
Efekt podání 5-MeO-DMT: terénní EEG studie u zdravých dobrovolníků ................................................. 28
Propustnost střeva a imunitní aktivace u psychózy: Korelační studie u pacientů
s první epizodou a zdravých kontrol ......................................................................................................... 28
Dynamika subjektivních příznaků a objektivních parametrů (aktivita/spánek)
v okolí relapsu bipolární poruchy ............................................................................................................... 29
Riziko žilního tromboembolismu při terapii antipsychotiky a antidepresivy – analýza
z registru RIETE ........................................................................................................................................ 29
VÝVĚSKOVÁ SDĚLENÍ .................................................................................................................... 30
Klinická K1–K14 ......................................................................................................................................... 30
Preklinická P1–P5 ...................................................................................................................................... 35
WORKSHOPY ..................................................................................................................................... 37
Deeskalace – základní intervence ke zvládaní agitovanosti a násilí ........................................................ 37
Algoritmus podávání off-label racemického ketaminu v psychiatrii .......................................................... 37
Pohádky 1000+1 noci (Vol. 2): Interaktivně pojaté kazuistické střípky
z psychedelických sezení u klientů s úzkostně-depresivním spektrem obtíží
v rámci ketaminem asistované psychoterapie na klinice Psyon ............................................................... 37
Psilocybin v klinické praxi – zkušenosti z klinických studií nejen z ČR ..................................................... 37
VOLNÁ SDĚLENÍ .............................................................................................................................. 38
Psychiatrické komplikace v onkologii ....................................................................................................... 38
Úloha fytoterapie v současné farmakoterapii a prevenci poruch nervového systému
a psychických poruch ............................................................................................................................... 38
Konopí pro léčebné využití v terapii nervových poruch a bolesti .............................................................. 38
Je editovanie génov budúcnosťou psychofarmakológie? ......................................................................... 39
REJSTŘÍK ................................................................................................................................................ 40
CONTENTS
EDITORIAL ................................................................................................................................................. 1
CONTENTS ................................................................................................................................................. 2
PROGRAM .............................................................................................................................................. 4
SCIENTIFIC SYMPOSIA ..................................................................................................................... 9
Symposium of the Czech Society for Biological Psychiatry: Clozapine in current
clinical practice ............................................................................................................................................ 9
Is there a place for the neurodiversity concept in psychiatry? ................................................................... 10
Olanzapine: a clinical practice manual ....................................................................................................... 11
Ketamine-assisted psychotherapy (KAP) in outpatient psychiatry ............................................................. 12
Symposium of the Czech Psychiatric Association: Psychiatry and society under pressure ....................... 13
Non-invasive brain stimulation (NIBS) in Czech psychiatry: clinical practice
and new approaches .................................................................................................................................. 14
Management of neuropsychiatric symptoms of dementia .......................................................................... 16
From the onset of eating disorders to chronicity, from pharmacotherapy to psychotherapy ....................... 17
Symposium of the National Institute of Mental Health ................................................................................ 19
Stem cell and brain organoid research in neuropsychiatric disorders ......................................................... 21
Psychedelics, problem children of psychopharmacology VI – translational
and preclinical studies ................................................................................................................................. 23
Psychopharmac detective stories 3rd .......................................................................................................... 24
Neurobiology of sleep in ADHD ................................................................................................................... 25
Psychedelics, problem children of psychopharmacology VI: From clinical trials
to clinical guidelines ...................................................................................................................................... 25
NEW RESEARCH .................................................................................................................................. 27
CYPRI: a tool for identifying patients suitable for pharmacogenetic testing in psychiatry ............................ 27
One-year outcomes after a 7-week inpatient addiction treatment program: analysis
of patients with alcohol use disorder ............................................................................................................ 27
Visual cognitive evoked potentials in acutely hospitalized patients with schizophrenia ............................... 27
Effect of administration on 5-MeO-DMT; an EEG field study in healthy volunteers ..................................... 28
Gut permeability and immune activation in psychosis: a correlation study
in first-episode patients and healthy controls ............................................................................................... 28
Dynamics of self-reported symptoms and objective parameters (aktivity/sleep)
around bipolar disorder relapse ................................................................................................................... 29
Risk of venous thromboembolism in patients treated with antipsychotics
and antidepressants – analysis from the RIETE registry .............................................................................. 29
POSTERS ................................................................................................................................................. 30
Clinical K1–K14 ............................................................................................................................................ 30
Preclinical P1–P5 ......................................................................................................................................... 35
WORKSHOPS ......................................................................................................................................... 37
Deescalation – basic interventions for coping with aggression and violence ............................................... 37
Algorithm for off-label use of ketamine in psychiatry .......................................................................... 37
One thousand and one nights tales (Vol. 2): Case vignettes from psychedelic sessions
in anxiety and depression spectrum disorders within ketamine-assisted psychotherapy
at Psyon Clinic ................................................................................................................................................. 37
Psilocybin in clinical practice – experiences from clinical studies not limited
to the Czech Republic .................................................................................................................................... 37
FREE COMMUNICATIONS .................................................................................................................. 38
Psychiatric complications in oncology ........................................................................................................... 38
The role of phytotherapy in contemporary pharmacotherapy and prevention
of nervous system disorders and mental disorders ....................................................................................... 38
Cannabis for medicinal use in the treatment of nervous disorders and pain ................................................. 38
Is gene editing the future of psychopharmacology? ....................................................................................... 39
INDEX........................................................................................................................................................... 40
